Search Results for 'egfr patients'

egfr patients published presentations and documents on DocSlides.

Audit of EGFR mutation testing in patients with proven Non-
Audit of EGFR mutation testing in patients with proven Non-
by aaron
On behalf of the North of England Cancer Network ...
Targeting EGFR Exon 20 insertions
Targeting EGFR Exon 20 insertions
by unita
Gregory J. Riely. November 2021. What about those ...
EGFR-Mutated Advanced NSCLC
EGFR-Mutated Advanced NSCLC
by sherrill-nordquist
The Coming Paradigm Shift. Faculty. Suresh S. Ram...
Best Practices in Nursing Management of EGFR Inhibitor Rash
Best Practices in Nursing Management of EGFR Inhibitor Rash
by olivia-moreira
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pr...
Anti-EGFR  induced  skin
Anti-EGFR induced skin
by berey
toxicity. ESDO Learning Bytes 2021. Dr Violaine RA...
EGFR Mutation in  Lung Adenocarcinoma (ADC)
EGFR Mutation in Lung Adenocarcinoma (ADC)
by QuietConfidence
Ana Rima. Lung Cancer: Incidence and Mortality. Ne...
Urine AlbumintoCreatinine Ratio UACRIn Evaluating Patients with Di
Urine AlbumintoCreatinine Ratio UACRIn Evaluating Patients with Di
by daniella
• More frequent monitoring may be indicated i...
Use of clinical laboratory databases to enable early identi
Use of clinical laboratory databases to enable early identi
by karlyn-bohler
Dr David Kennedy. Dr Hugh Rayner. Dr Jessie Raju....
Thierry
Thierry
by cheryl-pisano
Le Chevalier, . MD. The Role of Translational Res...
Surrogate or Not: The Role for
Surrogate or Not: The Role for
by cheryl-pisano
Cell Free Circulating . DNA in Detecting EGFR Mut...
Use of clinical laboratory databases to enable early identi
Use of clinical laboratory databases to enable early identi
by stefany-barnette
Dr David Kennedy. Dr Hugh Rayner. Dr Jessie Raju....
Detection of Mutations in EGFR in Circulating Lung-Cancer C
Detection of Mutations in EGFR in Circulating Lung-Cancer C
by sherrill-nordquist
Colin Reisterer and Nick Swenson. S. . Maheswaran...
Associations between Kidney Function and Subclinical Cardia
Associations between Kidney Function and Subclinical Cardia
by danika-pritchard
Park M et al. JASN September 2012. Renal Journal ...
Diabetic nephropathy s.Jafary
Diabetic nephropathy s.Jafary
by singh
. nodushan. Fellow of endocrinology. R...
Guideline for
Guideline for
by mackenzie
Page 1 of 6 April , 2015 t he Transition from t...
Using Non-targeted Therapies in Targeted Lung Cancer Popula
Using Non-targeted Therapies in Targeted Lung Cancer Popula
by ellena-manuel
Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
1/2015 Samuel Lai Contrast Nephropathies
1/2015 Samuel Lai Contrast Nephropathies
by celsa-spraggs
Understand the interaction between iodine, gadoli...
Please note, these are the actual video-recorded
Please note, these are the actual video-recorded
by chaptoe
proceedings from the live CME event and may includ...
Lung cancer Treatment
Lung cancer Treatment
by attentionallianz
Consequences of the Lack of Patients of color &...
Please note, these are the
Please note, these are the
by markes
actual. . video-recorded proceedings from the . l...
ACC – Washington DC Monday April 4, 2022
ACC – Washington DC Monday April 4, 2022
by TinyTeddy
Featured Clinical Research – Late Breaking Clini...
A brief overview of CKD
A brief overview of CKD
by sadie
Harshani D. Perera . Senior Registrar – Nephrolo...
Prise en charge des patients
Prise en charge des patients
by ethlyn
insuffisants cardiaques ET insuffisants rénaux :....
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
by southan
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pra...
Chronic Kidney Disease and Cardiovascular Risk
Chronic Kidney Disease and Cardiovascular Risk
by Younggunner
Heather Mascio, DO. Introduction. Chronic Kidney D...
Department of GI Medical Oncology
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
Where we are with targeted
Where we are with targeted
by stefany-barnette
therapies . for . cholangiocarcinoma. Professor J...
Pharmacologic Approaches to Treating CKD in Type 2 DM (1)
Pharmacologic Approaches to Treating CKD in Type 2 DM (1)
by calandra-battersby
Metformin must be considered the cornerstone of t...
Renal Replacement Therapy: What the PCP Needs to Know
Renal Replacement Therapy: What the PCP Needs to Know
by tatiana-dople
Learning Objectives. Describe treatment options f...
Analytical Team Faye Cleary
Analytical Team Faye Cleary
by phoebe-click
Lois Kim. Dr Sally Hull. Dr . Ben Caplin. Profess...
NCI-Molecular Analysis for Therapy Choice
NCI-Molecular Analysis for Therapy Choice
by phoebe-click
(NCI-MATCH or EAY131). Interim Analysis Results....
Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi
Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi
by conchita-marotz
A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borka...
Please note, these are the
Please note, these are the
by disclaimercanon
actual. . video-recorded proceedings from the . l...
The Role of Antiangiogenic Agents
The Role of Antiangiogenic Agents
by luanne-stotts
The Role of Antiangiogenic Agents in the Changin...
Safety   of  Tenofovir
Safety of Tenofovir
by deandre922
Alafenamide. in Renal Impairment. A Pozniak. 1. ,...
Clinical Controversies:  Recent Updates for Medication Use in Chronic Kidney Disease
Clinical Controversies: Recent Updates for Medication Use in Chronic Kidney Disease
by amey
Tracy Anderson-Haag, . PharmD. , BCPS. Clinical Ph...